Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,046 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epilepsy Clear all
Terminated Not applicable Interventional

Pre-oxygenation and Measures of Gas Exchanges During Seizures in the Epilepsy Monitoring Unit

NCT02241798
View directory record Official record
Conditions
Epilepsy
Interventions
oxygen
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 4, 2026, 9:41 AM EDT
Enrolling by invitation Not applicable Interventional

Causal Role of Top-Down Theta Oscillations in Prioritization

NCT06252532
View directory record Official record
Conditions
Working Memory, Epilepsy
Interventions
Direct cortical stimulation (DCS) Alpha, Direct cortical stimulation (DCS) Theta, Sham Direct cortical stimulation (DCS), Direct cortical stimulation (DCS) In-Phase Theta, Direct cortical stimulation (DCS) Anti-Phase Theta
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 9:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Balance and Anti-Epileptic Drugs

NCT03338478
View directory record Official record
Conditions
Epilepsy
Interventions
Wii Balance Board
Diagnostic Test
Lead sponsor
Erik J. Kobylarz
Other
Eligibility
16 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 4, 2026, 9:41 AM EDT
Completed Phase 4 Interventional

Epidiolex® for Anxiety in Pediatric Epilepsy

NCT05324449
View directory record Official record
Conditions
Anxiety, Epilepsy
Interventions
Cannabidiol 100 MG/ML
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 4, 2026, 9:41 AM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Interictal Dysfunction in Epilepsy

NCT02950506
View directory record Official record
Conditions
Epilepsy
Interventions
transcranial direct current stimulation, Cognitive Remediation Therapy
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 4, 2026, 9:41 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

NCT07775976
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions
COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
Device · Other
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Pasadena, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 9:41 AM EDT
Recruiting Phase 4 Interventional

Medication Treatment of ADHD in Pediatric Epilepsy

NCT07594652
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate hydrochloride (Jornay PM)
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 9:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

NCT02497235
View directory record Official record
Conditions
Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
Interventions
TAK-935, [18F]MNI-792 (tracer)
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 4, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional Results available

Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)

NCT01891890
View directory record Official record
Conditions
Epilepsy, Partial, Epilepsy, Localization Related
Interventions
Oxcarbazepine, Levetiracetam, Lamotrigine
Drug
Lead sponsor
Emory University
Other
Eligibility
5 Years to 16 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Little Rock, Arkansas • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 4, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 4, 2026, 9:41 AM EDT
No Longer Available No phase listed Expanded access

Stiripentol in Dravet Syndrome

NCT01533506
View directory record Official record
Conditions
Dravet Syndrome
Interventions
stiripentol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
11 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 4, 2026, 9:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

NCT06063850
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
AAV9-hSyn1-miGRIK2
Genetic
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 4, 2026, 9:41 AM EDT
Completed No phase listed Observational

Rolandic Epilepsy Genomewide Association International Study

NCT03547050
View directory record Official record
Conditions
Rolandic Epilepsy
Interventions
Blood draw, Existing samples
Other
Lead sponsor
King's College London
Other
Eligibility
6 Years to 25 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
New York, New York • Providence, Rhode Island • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 4, 2026, 9:41 AM EDT
Completed No phase listed Observational

Bone Mineral Density in Pediatric Epilepsy

NCT00204815
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
8 Years to 18 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 4, 2026, 9:41 AM EDT
Completed Phase 3 Interventional

Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy

NCT00436631
View directory record Official record
Conditions
Epilepsy
Interventions
Dietary management of seizures
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Sep 4, 2026, 9:41 AM EDT
Completed No phase listed Observational

A Complex Contraception Registry

NCT02219269
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease, Epilepsy, Migraine, Neurological Disorders, Cancer, Bariatric Surgery Candidate, Organ or Tissue Transplant; Complications, Lupus Erythematosus, Systemic, Other Hematologic Conditions, Other Venous Embolism and Thrombosis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 4, 2026, 9:41 AM EDT
Completed No phase listed Observational

Detecting Absence Seizures Using Eye Tracking

NCT04439656
View directory record Official record
Conditions
Epilepsy, Generalized, Absence Epilepsy, Absence Seizures, Seizures, Seizure Disorder
Interventions
Eye movement analysis
Diagnostic Test
Lead sponsor
Rachel Kuperman
Industry
Eligibility
4 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Orange, California • San Diego, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 4, 2026, 9:41 AM EDT
Active, not recruiting Phase 1 Interventional

BHV-7000 Responsive Neurostimulation System (RNS) Study

NCT07125261
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
BHV-700
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 9:41 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics of Nasal and Buccal Midazolam Using EEG

NCT01316445
View directory record Official record
Conditions
Epilepsy
Interventions
nasal Midazolam
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Sep 4, 2026, 9:41 AM EDT
Not listed Not applicable Interventional

Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients with Acupuncture Treatment

NCT04677751
View directory record Official record
Conditions
Epilepsy
Interventions
Acupuncture intervention
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 4, 2026, 9:41 AM EDT
Recruiting No phase listed Observational

Patterns of Neurodevelopmental Disorders

NCT06213090
View directory record Official record
Conditions
Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions
Not listed
Lead sponsor
Richard Frye
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 4, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

NCT07445074
View directory record Official record
Conditions
Epilepsy, Seizure
Interventions
Medilepsy® Chatbot AI-Enhanced, Medilepsy® Chatbot Standard
Other
Lead sponsor
University of Central Florida
Other
Eligibility
14 Years to 24 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 4, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

NCT00355082
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
lamotrigine, 300 mg/day, lamotrigine, 250 mg/day
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
67
States / cities
Alabaster, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 4, 2026, 9:41 AM EDT
Terminated Phase 1 Interventional

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

NCT02134067
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TAS-119, Paclitaxel
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 4, 2026, 9:41 AM EDT